THERAPY DOSSIER · th-3cb5374d586d

XCT790

Drug · ChEMBL compound_search 'XCT790' returned 0 hits, an explicit searched negative result (XCT790 is an ERR-alpha inverse agonist research tool compound). ClinicalTrials.gov 'XCT790 OR ERR-alpha inverse agonist' returned 0 hits. No human translation at either entity or class level.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: ChEMBL compound_search 'XCT790' returned 0 hits, an explicit searched negative result (XCT790 is an ERR-alpha inverse agonist research tool compound). ClinicalTrials.gov 'XCT790 OR ERR-alpha inverse agonist' returned 0 hits. No human translation at either entity or class level.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25665753 ↗2015Reported harm

The effect of estrogen-related receptor alpha on the regulation of angiogenesis after spinal cord injury.

RatSpinal cord injuryContusionSprague-DawleyMaleInjection (route not specified in the abstract)First dose 30 min after contusion

Model: Acute traumatic spinal cord injury by modified Allen weight-drop contusion

XCT790 aggravated tissue damage, reduced ERRalpha-positive cells, repressed ERRalpha, VEGF and angiopoietin-2 expression and decreased vascular density and endothelial proliferation, indicating that ERRalpha mediates angiogenesis after spinal cord injury. The compound was used as a mechanistic bloc…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…